Validation of new cancer biomarkers: A position statement from the european group on tumor markers

Clinical Chemistry

Volumn 61, Issue 6, 2015, Pages 809-820

  Duffy, Michael J ^a   Sturgeon, Catharine M ^b   Sölétormos, György ^c   Barak, Vivian ^d   Molina, Rafael ^e   Hayes, Daniel F ^f   Diamandis, Eleftherios P ^g   Bossuyt, Patrick M M ^h  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c HILLERØD HOSPITAL   (Denmark)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANALYTICAL PARAMETERS; ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOHISTOCHEMISTRY; OCCULT BLOOD; OVARY CANCER; PREDICTIVE VALUE; PROSTATE CANCER; QUANTITATIVE ASSAY; SAMPLE; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; CLINICAL CHEMISTRY; EUROPE; HEALTH CARE COST; LABORATORY DIAGNOSIS; NEOPLASMS; PILOT STUDY; PROCEDURES; REPRODUCIBILITY;

CLINICAL CHEMISTRY TESTS; EUROPE; HEALTH CARE SECTOR; HUMANS; NEOPLASMS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84930520177     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.239863     Document Type: Article

References (78)

1. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 2013;22:4-11.
2. Paoletti C, Hayes DF. Molecular testing in breast cancer. Annu Rev Med 2014;65:95-110.
3. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102: 1462-7.
4. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, et al. Breaking a vicious cycle Sci Transl Med 2013;5:196cm6.
5. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1-10.
6. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112-23.
7. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
8. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2011;135:537-43.
9. Peña-Llopis S, Brugarolas J. Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. Nat Protoc 2013;8: 2240-55.
10. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015;27:15-26.
11. Hergenhahn M, Kenzelmann M, Gröne HJ. Laser-controlled microdissection of tissues opens a window of new opportunities. Pathol Res Pract 2003;199:419-23.
12. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95. Erratum in: J Clin Oncol 2010;28:3543.
13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, Mc-Shane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
14. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15:415-53.
15. García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura P, García-Carbonero R, Musulén-Palet E, et al. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015;17:264-73.
16. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 2014;67:923-31.
17. Micheel C, Nass SJ, Omenn GS, Institute of Medicine. Evolution of translational omics: lessons learned and the path forward. Micheel C, Nass SJ, Omenn GS, eds. Washington (DC): National Academies Press; 2012. Available from http://www.nap.edu/catalog.php?record-id=13297.
18. Horvath AR, Lord SJ, St John A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta 2014;427:49-57.
19. Biesecker LG, Green RC. Diagnostic and clinical genome and exome sequencing. N Engl J Med 2014; 370:2418-25.
20. Markopoulos C. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer. Expert Rev Anticancer Ther 2013;13:179-94.
21. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009;9:417-22.
22. Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;452:16:3299-318.
23. Jennings L, Van Deerlin VM, Gulley ML; College of American Pathologists Molecular Pathology Resource Committee. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 2009;133:743-55.
24. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
25. Williams PM, Lively TG, Jessup JM, Conley BA. Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 2012;18: 1531-9.
26. Fraser CG, Kallner A, Kenny D, Petersen PH. Introduction: strategies to set global quality specifications in laboratory medicine. Scand J Clin Lab Invest 1999;59:477-8.
27. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use-a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010;4:892-903.
28. Prassas I, Diamandis EP. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clin Chem Lab Med 2014;52:765-6.
29. Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, et al. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin Chem 2014;60:381-8.
30. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009;101:1453-63.
31. Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-7.
32. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;51:42-9.
33. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010;28:698-704.
34. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
35. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-74.
36. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 2011;4:375-83.
37. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8.
38. Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005;97:866-7.
39. Tinker AV, Boussioutas A, Bowtell DD. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 2006;9:333-9.
40. Berry D. Multiplicities in cancer research: ubiquitous and necessary evils. J Natl Cancer Inst 2012;104:1124-32.
41. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1-32.
42. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20:1428-44.
43. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
44. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
45. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013;31:4562-8.
46. Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing cancer care: a systematic review and classification. Clin Cancer Res 2013;19:4578-88.
47. Sargent DJ, Korn EL. Decade in review-clinical trials: shifting paradigms in cancer clinical trial design. Nat Rev Clin Oncol 2014;11:625-6.
48. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, et al. Methylated genes as new cancer biomarkers. Eur J Cancer 2009;45:335-46.
49. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
50. Lord SJ, Irwig L, Bossuyt PMM. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making 2009;29:E1-12.
51. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis Clin Med 2001;1:478-84.
52. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
53. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
54. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-92.
55. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013;49:1825-35.
56. Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;141:13-22.
57. Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013;133:929-36.
58. Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13.
59. US Food and Drug Administration. Draft guidance for industry, Food and Drug Administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.pdf (Accessed November 2014).
60. Pignatti F, Ehmann F, Hemmings R, Jonsson B, Nuebling M, Papaluca-Amati M, et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin Cancer Res 2014;20:1458-68.
61. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem 2011;48:295-9.
62. Duffy MJ, Crown J. Precision treatment for cancer: role of prognostic and predictive markers. Crit Rev Clin Lab Sci 2014;51:30-45.
63. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43:2559-79.
64. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011;8:171-6.
65. Rifai N, Bossuyt PM, Ioannidis JP, Bray KR, McShane LM, Golub RM, Hooft L. Registering diagnostic and prognostic trials of tests: is it the right thing to do? Clin Chem 2014;60:1146-52.
66. Rifai N, Annesley TM, Berg JP, Brugnara C, Delvin E, Lamb EJ, Ness PM, et al. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Clin Chem 2012;58:483-5.
67. Moore HM, Kelly A, McShane LM, Vaught J. Biospecimen reporting for improved study quality (BRISQ). Clin Chim Acta 2012;413:1305.
68. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
69. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49:7-18.
70. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
71. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012;10:51.
72. Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, et al. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem 2013;59:52-9.
73. Hall JA, Salgado R, Lively T, Sweep F, Schuh A. A riskmanagement approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncol 2014;15:e184-93.
74. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, et al. Criteria for the use of omics-based predictors in clinical trials. Nature 2013;502:317-20.
75. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med. 2013 Oct 17;11:220.
76. Deutsch EW, Ball CA, Berman JJ, Bova GS, Brazma A, Bumgarner RE, et al. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 2008;26:305-12.
77. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
78. McShane LM, Hayes DF. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 2012;30:4223-32.